Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04814719 · ClinicalTrials.gov registry record
Treatment and Duration Effect of Pentosan Polysulfate Sodium (PPS) in Participants With Knee Osteoarthritis Pain
A clinical trial, sponsored by Paradigm Biopharmaceuticals.
- Completed
- Registry status
- 133
- Enrollment target
NCT04814719 is a clinical trial that has completed, run by Paradigm Biopharmaceuticals. The registered enrollment target is 133 participants.
The verdict
NCT04814719 has completed, sponsored by Paradigm Biopharmaceuticals.
- COMPLETED
- Registry status
- 133 participants
- Enrollment target
Study Summary
The purpose of this study is to measure the duration of treatment effect with subcutaneous injections of pentosan polysulfate sodium (PPS) compared with placebo in adult participants with knee osteoarthritis (OA) pain. The study duration will be up to 34 weeks. Participants who completed pDay 162 of Study PARA\_OA\_002 (i.e. did not discontinue/withdraw prematurely from the parent study) will be invited to participate.
Interventions
- DRUG Placebo (Sodium Chloride Injection, 0.9%)
- DRUG Pentosan Polysulphate Sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2023-06-24 |
| Est. Completion | 2024-12-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04814719
The ClinicalTrials.gov registry entry for NCT04814719 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Paradigm Biopharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo (Sodium Chloride Injection, 0.9%) is the first listed.
NCT04814719 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04814719 about?
NCT04814719 is a clinical study titled "Treatment and Duration Effect of Pentosan Polysulfate Sodium (PPS) in Participants With Knee Osteoarthritis Pain". The purpose of this study is to measure the duration of treatment effect with subcutaneous injections of pentosan polysulfate sodium (PPS) compared with placebo in adult participants with knee osteoarthritis (OA) pain. The study duration will be up to 34 weeks. Participants who completed pDay 162 o...
What is the current status of trial NCT04814719?
This trial is currently completed. The enrollment target is 133 participants. The study started on 2023-06-24. Estimated completion is 2024-12-24.
What interventions are being tested in trial NCT04814719?
The interventions under investigation include: Placebo (Sodium Chloride Injection, 0.9%) (DRUG), Pentosan Polysulphate Sodium (DRUG).
Who is sponsoring clinical trial NCT04814719?
This trial is sponsored by Paradigm Biopharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.